Clinical Trial Update: A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed [Phase 2]

View source ↗

Summary

Phase 2 study evaluating switching to rilpivirine-containing regimens in virologically suppressed HIV-1-infected children aged 2 to <12 years. Results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Edurant (rilpivirine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: HIV | Phase 2 | Status: COMPLETED | Results posted: 2024-05-02